Lixte Biotechnology Holdings Inc (LIXT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) has a cash flow conversion efficiency ratio of -0.099x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.09 Million) by net assets ($10.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LIXT equity financing ratio to measure how much of total assets are equity-financed.
Lixte Biotechnology Holdings Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Lixte Biotechnology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lixte Biotechnology Holdings Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Lixte Biotechnology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Luxury Real Estate Investment Fund
BK:LUXF
|
-0.005x |
|
Fluence Corporation Limited
F:4SVE
|
0.638x |
|
DKME Co., Ltd.
KO:015590
|
0.062x |
|
Nimbus Group AB
ST:BOAT
|
-0.017x |
|
Ways Technical Ltd
TWO:3508
|
-0.047x |
|
De Nora India Limited
NSE:DENORA
|
0.179x |
|
Tune Protect Group Bhd
KLSE:5230
|
0.004x |
|
EgnsINVEST Ejendomme Tyskland A/S
CO:EGNETY
|
0.003x |
Annual Cash Flow Conversion Efficiency for Lixte Biotechnology Holdings Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lixte Biotechnology Holdings Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see LIXT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.96 Million | $-3.07 Million | -0.280x | +92.68% |
| 2024-12-31 | $827.22K | $-3.16 Million | -3.826x | -255.95% |
| 2023-12-31 | $3.99 Million | $-4.29 Million | -1.075x | -20.37% |
| 2022-12-31 | $5.17 Million | $-4.61 Million | -0.893x | -3.24% |
| 2021-12-31 | $4.79 Million | $-4.14 Million | -0.865x | -103.37% |
| 2020-12-31 | $5.01 Million | $-2.13 Million | -0.425x | +38.17% |
| 2019-12-31 | $2.43 Million | $-1.67 Million | -0.688x | -87.80% |
| 2018-12-31 | $4.13 Million | $-1.51 Million | -0.366x | +74.19% |
| 2017-12-31 | $995.04K | $-1.41 Million | -1.419x | +81.83% |
| 2016-12-31 | $214.76K | $-1.68 Million | -7.811x | -11.85% |
| 2015-12-31 | $312.33K | $-2.18 Million | -6.983x | -13.52% |
| 2014-12-31 | $265.86K | $-1.64 Million | -6.152x | -23.17% |
| 2013-12-31 | $236.27K | $-1.18 Million | -4.995x | -518.00% |
| 2012-12-31 | $1.49 Million | $-1.21 Million | -0.808x | +95.30% |
| 2011-12-31 | $79.02K | $-1.36 Million | -17.206x | -3090.42% |
| 2010-12-31 | $1.74 Million | $-936.39K | -0.539x | -9.91% |
| 2009-12-31 | $1.30 Million | $-638.44K | -0.491x | -126.56% |
| 2008-12-31 | $-323.55K | $-597.69K | 1.847x | +199.06% |
| 2007-12-31 | $376.93K | $-702.87K | -1.865x | -163.47% |
| 2006-12-31 | $626.56K | $-443.45K | -0.708x | -116.94% |
| 2005-12-31 | $-7.87K | $-32.87K | 4.177x | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-… Read more